Search
Benznidazole
go.drugbank.com/drugs/DB11989ApprovedInvestigationalBenznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.
Fedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigational[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigational[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … Delgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
Synonyms: -OXO-6-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (3S,4R)-, 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrileTriamterene
go.drugbank.com/drugs/DB00384Approved[T28] Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia.
Mixtures: Nu-triazide Tab 50 Mg/25 mgSevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia.
Eribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated ...
Sodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Mixtures: Urin D/S, Uretron D/SRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. … [A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 [A18745] and accelerated approval in December 2016.
Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is